Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Non-Melanoma Skin Cancer (NMSC) 1Neoplasms 1Hypogonadism 1Fatigue 1Eunuchism 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Gels × 1 year × Clear all
NCT04301765 2026-03-31

TEMEC

Seattle Institute for Biomedical and Clinical Research

Phase 2 Recruiting
230 enrolled

Eunuchism, Fatigue, Hypogonadism, Neoplasms

NCT07201376 2026-02-06

PPIX

Dartmouth-Hitchcock Medical Center

Recruiting
125 enrolled
Dermatologic

Non-Melanoma Skin Cancer (NMSC)

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Mayo Clinic

Phase 2 Terminated
65 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡